In Brief: Cardiovascular Diagnostics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Files 510(k) submissions for its Escarin Clotting Time test and Low Range Heparin Management Test. Both tests are based upon CDI's Thrombolytic Assessment System technology, the firm states. The ECT test is intended for use in monitoring the action of Knoll-AG's PEG-Hirudin thrombin inhibitor, for which dosage parameters in the treatment of unstable angina are narrow, the firm explains. The LHMT test is intended for use in measuring heparin levels during cardiac catheterization...
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.